Circulating tumor cells in breast cancer-current status and perspectives

Critical Reviews in Oncology/Hematology

Volumn 97, Issue , 2016, Pages 22-29

  Banys Paluchowski, Malgorzata ^a,b   Krawczyk, Natalia ^a   Meier Stiegen, Franziska ^a   Fehm, Tanja ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Gynecology and Obstetrics ^*  (Germany)

Author keywords

Biomarkers; Breast cancer; Circulating tumor cell; Disseminated tumor cell; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL FUNCTION; CELL SELECTION; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; EARLY CANCER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; OVERALL SURVIVAL; PATIENT MONITORING; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR BIOPSY; BLOOD; BREAST NEOPLASMS; FEMALE; METASTASIS; PATHOLOGY; PHYSIOLOGIC MONITORING; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MONITORING, PHYSIOLOGIC; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84951758054     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.10.010     Document Type: Review

References (85)

1. Agelaki S., Kalykaki A., Markomanolaki H., Papadaki M.A., Kallergi G., Hatzidaki D., Kalbakis K., Mavroudis D., Georgoulias V. Efficacy of lapatinib in therapy-resistant HER2-positive circulating tumor cells in metastatic breast cancer. PloS One 2015, 10(6):e0123683.
2. Alix-Panabieres C., Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 2013, 59(1):110-118.
3. Ashworth T.R. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust. Med. J. 1869, 14:146-149.
4. Banys M., Krawczyk N., Becker S., Jakubowska J., Staebler A., Wallwiener D., Fehm T., Rothmund R. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res. Treat. 2012, 132(1):121-129.
5. Benoy I.H., Elst H., Philips M., Wuyts H., Van Dam P., Scharpe S., Van Marck E., Vermeulen P.B., Dirix L.Y. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br. J. Cancer 2006, 94(5):672-680.
6. Bernhard H., Neudorfer J., Gebhard K., Conrad H., Hermann C., Nahrig J., Fend F., Weber W., Busch D.H., Peschel C. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 2008, 57(2):271-280.
7. Bidard F.C., Vincent-Salomon A., Sigal-Zafrani B., Dieras V., Mathiot C., Mignot L., Thiery J.P., Sastre-Garau X., Pierga J.Y. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann. Oncol. 2008, 19(3):496-500.
8. Bidard F.C., Mathiot C., Delaloge S., Brain E., Giachetti S., de Cremoux P., Marty M., Pierga J.Y. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 2010, 21(4):729-733.
9. Bidard F.C., Fehm T., Ignatiadis M., Smerage J.B., Alix-Panabieres C., Janni W., Messina C., Paoletti C., Muller V., Hayes D.F., et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013, 32(1-2):179-188.
10. Bidard F.C., Belin L., Delaloge S., Lerebours F., Ngo C., Reyal F., Alran S., Giacchetti S., Marty M., Lebofsky R., et al. Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 study. Int. J. Breast Cancer 2013, 2013(130470).
11. Bidard F.C., Peeters D.J., Fehm T., Nole F., Gisbert-Criado R., Mavroudis D., Grisanti S., Generali D., Garcia-Saenz J.A., Stebbing J. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014, 15(4):406-414.
12. Bidard F.-C., Peeters D.J., Fehm T., Nolé F., Gisbert-Criado R., Mavroudis D., Grisanti S., Generali D., Garcia-Saenz J.A., Stebbing J., et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014, 15(4):406-414.
13. Bozionellou V., Mavroudis D., Perraki M., Papadopoulos S., Apostolaki S., Stathopoulos E., Stathopoulou A., Lianidou E., Georgoulias V. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 2004, 10(24):8185-8194.
14. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005, 353(8):793-802.
15. Broersen L.H., van Pelt G.W., Tollenaar R.A., Mesker W.E. Clinical application of circulating tumor cells in breast cancer. Cell Oncol. (Dordr.) 2014, 37(1):9-15.
16. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., Matera J., Repollet M., Doyle G.V., Terstappen L.W. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006, 12(21):6403-6409.
17. Cann G.M., Gulzar Z.G., Cooper S., Li R., Luo S., Tat M., Stuart S., Schroth G., Srinivas S., Ronaghi M., et al. mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One 2012, 7(11):e49144.
18. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351(8):781-791.
19. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., Doyle G.V., Matera J., Allard W.J., Miller M.C. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 2005, 23(7):1420-1430.
20. Dawson S.J., Tsui D.W., Murtaza M., Biggs H., Rueda O.M., Chin S.F., Dunning M.J., Gale D., Forshew T., Mahler-Araujo B., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368(13):1199-1209.
21. Dawson S.J., Rosenfeld N., Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 369(1):93-94.
22. De G., iorgi U., Valero V., Rohren E., Dawood S., Ueno N.T., Miller M.C., Doyle G.V., Jackson S., Andreopoulou E., Handy B.C., et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J. Clin. Oncol. 2009, 27(20):3303-3311.
23. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
24. Fehm T., Banys M. Circulating free DNA: a new surrogate marker for minimal residual disease?. Breast Cancer Res. Treat. 2011.
25. Fehm T., Krawczyk N., Solomayer E.F., Becker-Pergola G., Durr-Storzer S., Neubauer H., Seeger H., Staebler A., Wallwiener D., Becker S. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res. 2008, 10(5):R76.
26. Fehm T., Hoffmann O., Aktas B., Becker S., Solomayer E.F., Wallwiener D., Kimmig R., Kasimir-Bauer S. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009, 11(4):R59.
27. Fehm T., Muller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., Lattrich C., Lohberg C.R., Solomayer E., Rack B., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 2010, 124(2):403-412.
28. Fischer J.C., Niederacher D., Topp S.A., Honisch E., Schumacher S., Schmitz N., Zacarias Fohrding L., Vay C., Hoffmann I., Kasprowicz N.S. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(41):16580-16585.
29. Franken B., de Groot M.R., Mastboom W.J., Vermes I., van der Palen J., Tibbe A.G., Terstappen L.W. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012, 14(5):R133.
30. Freidin M.B., Tay A., Freydina D.V., Chudasama D., Nicholson A.G., Rice A., Anikin V., Lim E. An assessment of diagnostic performance of a filter-based antibody-independent peripheral blood circulating tumour cell capture paired with cytomorphologic criteria for the diagnosis of cancer. Lung Cancer 2014, 85(2):182-185.
31. Giordano A., Giuliano M., De Laurentiis M., Arpino G., Jackson S., Handy B.C., Ueno N.T., Andreopoulou E., Alvarez R.H., Valero V., et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann. Oncol. 2012, 23(5):1144-1150.
32. Giuliano M., Giordano A., Jackson S., Hess K.R., De Giorgi U., Mego M., Handy B.C., Ueno N.T., Alvarez R.H., De Laurentiis M., et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011, 13(3):R67.
33. Hall C., Karhade M., Laubacher B., Anderson A., Kuerer H., DeSynder S., Lucci A. Circulating tumor cells after neoadjuvant chemotherapy in stage I-III triple-negative breast cancer. Ann. Surg. Oncol. 2015, (Epub ahead of print).
34. Harb W., Fan A., Tran T., Danila D.C., Keys D., Schwartz M., Ionescu-Zanetti C. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl. Oncol. 2013, 6(5):528-538.
35. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., Matera J., Allard W.J., Doyle G.V., Terstappen L.W. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006, 12(14 (Pt. 1)):4218-4224.
36. Helissey C., Berger F., Cottu P., Dieras V., Mignot L., Servois V., Bouleuc C., Asselain B., Pelissier S., Vaucher I., et al. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. Cancer Lett. 2015, 360(2):213-218.
37. Hou H.W., Warkiani M.E., Khoo B.L., Li Z.R., Soo R.A., Tan D.S., Lim W.T., Han J., Bhagat A.A., Lim C.T. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci. Rep. 2013, 3:1259.
38. Hwang S.B., Bae J.W., Lee H.Y., Kim H.Y. Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer. J. Breast Cancer 2012, 15(1):34-42.
39. Ignatiadis M., Xenidis N., Perraki M., Apostolaki S., Politaki E., Kafousi M., Stathopoulos E.N., Stathopoulou A., Lianidou E., Chlouverakis G., et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 2007, 25(33):5194-5202.
40. Ignatiadis M., Perraki M., Apostolaki S., Politaki E., Xenidis N., Kafousi M., Stathopoulos E., Lianidou E., Sotiriou C., Georgoulias V. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Clin. Breast Cancer 2007, 7(11):883-889.
41. Janni W., Vogl F.D., Wiedswang G., Synnestvedt M., Fehm T., Juckstock J., Borgen E., Rack B., Braun S., Sommer H., et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse- a European pooled analysis. Clin. Cancer Res. 2011, 17(9):2967-2976.
42. Janni W.J., Rack B.K., Terstappen L.M.W.W., Pierga J.-Y., Fehm T., Hall C., Groot M., Bidard F.-C., Meier-Stiegen F., Friedl T.W.P., et al. A pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer. San Antonio Breast Cancer Symposium Abstract PD6-6. Cancer Res. 2013, 15(73).
43. Khoo B.L., Lee S.C., Kumar P., Tan T.Z., Warkiani M.E., Ow S.G., Nandi S., Lim C.T., Thiery J.P. Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget 2015, 6(17):15578-15593.
44. Krawczyk N., Banys M., Neubauer H., Solomayer E.F., Gall C., Hahn M., Becker S., Bachmann R., Wallwiener D., Fehm T. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 2009, 29(10):4019-4024.
45. Krawczyk N., Meier-Stiegen F., Banys M., Neubauer H., Ruckhaeberle E., Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed. Res. Int. 2014, 2014:415721.
46. Kulemann B., Pitman M.B., Liss A.S., Valsangkar N., Fernandez-Del Castillo C., Lillemoe K.D., Hoeppner J., Mino-Kenudson M., Warshaw A.L., Thayer S.P. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas 2015, 44(4):547-550.
47. Kuniyoshi R.K., de Sousa Gehrke F., Alves B.C., Vilas-Boas V., Colo A.E., Sousa N., Nunes J., Fonseca F.L., Del Giglio A. Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer. Tumour Biol. 2015.
48. Lin H.K., Zheng S., Williams A.J., Balic M., Groshen S., Scher H.I., Fleisher M., Stadler W., Datar R.H., Tai Y.C. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin. Cancer Res. 2010, 16(20):5011-5018.
49. Liu M.C., Shields P.G., Warren R.D., Cohen P., Wilkinson M., Ottaviano Y.L., Rao S.B., Eng-Wong J., Seillier-Moiseiwitsch F., Noone A.M., et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 2009, 27(31):5153-5159.
50. Lucci A., Hall C.S., Lodhi A.K., Bhattacharyya A., Anderson A.E., Xiao L., Bedrosian I., Kuerer H.M., Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012, 13(7):688-695.
51. Mego M., Giordano A., De Giorgi U., Masuda H., Hsu L., Giuliano M., Fouad T.M., Dawood S., Ueno N.T., Valero V., et al. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 2015, 17:2.
52. Melcher C., Schochter F., Albrecht S. DETECT IV. - a multicenter, single arm, phase II study evaluating the efficacy of Everolimus in combination with endocrine therapy in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and exclusively HER2-negative circulating tumor cells (CTCs). Oncol. Res. Treat. 2014, 37:29.
53. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., Beitsch P., Khan A., Euhus D., Osborne C., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(25):9393-9398.
54. Molloy T.J., Bosma A.J., Baumbusch L.O., Synnestvedt M., Borgen E., Russnes H.G., Schlichting E., van't Veer L.J., Naume B. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res. 2011, 13(3):R61.
55. Muller V., Stahmann N., Riethdorf S., Rau T., Zabel T., Goetz A., Janicke F., Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin. Cancer Res. 2005, 11(10):3678-3685.
56. Muller V., Riethdorf S., Rack B., Janni W., Fasching P.A., Solomayer E., Aktas B., Kasimir-Bauer S., Pantel K., Fehm T., et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Research BCR 2012, 14(4):R118.
57. Nagrath S., Sequist L.V., Maheswaran S., Bell D.W., Irimia D., Ulkus L., Smith M.R., Kwak E.L., Digumarthy S., Muzikansky A. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450(7173):1235-1239.
58. Nakamura S., Yagata H., Ohno S., Yamaguchi H., Iwata H., Tsunoda N., Ito Y., Tokudome N., Toi M., Kuroi K., et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010, 17(3):199-204.
59. Neves R.P., Raba K., Schmidt O., Honisch E., Meier-Stiegen F., Behrens B., Mohlendick B., Fehm T., Neubauer H., Klein C.A. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer. Clin. Chem. 2014, 60(10):1290-1297.
60. Nole F., Munzone E., Zorzino L., Minchella I., Salvatici M., Botteri E., Medici M., Verri E., Adamoli L., Rotmensz N., et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann. Oncol. 2008, 19(5):891-897.
61. Ozkumur E., Shah A.M., Ciciliano J.C., Emmink B.L., Miyamoto D.T., Brachtel E., Yu M., Chen P.I., Morgan B., Trautwein J., et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci. Transl. Med. 2013, 5(179). 179ra147.
62. Paget S. Distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571.
63. Paoletti C., Muniz M.C., Thomas D.G., Griffith K.A., Kidwell K.M., Tokudome N., Brown M.E., Aung K., Miller M.C., Blossom D.L. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin. Cancer Res. 2015, 21(11):2487-2498.
64. Pestrin M., Bessi S., Puglisi F., Minisini A.M., Masci G., Battelli N., Ravaioli A., Gianni L., Di Marsico R., Tondini et al C. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with ER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res. Treat. 2012, 134(1):283-289.
65. Pierga J.Y., Bidard F.C., Mathiot C., Brain E., Delaloge S., Giachetti S., de C., Remoux P., Salmon R., Vincent-Salomon A., Marty M. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin. Cancer Res. 2008, 14(21):7004-7010.
66. Pierga J.Y., Hajage D., Bachelot T., Delaloge S., Brain E., Campone M., Dieras V., Rolland E., Mignot L., Mathiot C., et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. 2012, 23(3):618-624.
67. Pierga J.Y., Petit T., Levy C., Ferrero J.M., Campone M., Gligorov J., Lerebours F., Roche H., Bachelot T., Charafe-Jauffret E., et al. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. Clin. Cancer Res. 2015, 21(6):1298-1304.
68. Polzer B., Medoro G., Pasch S., Fontana F., Zorzino L., Pestka A., Andergassen U., Meier-Stiegen F., Czyz Z.T., Alberter B. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol. Med. 2014, 6(11):1371-1386.
69. Powell A.A., Talasaz A.H., Zhang H., Coram M.A., Reddy A., Deng G., Telli M.L., Advani R.H., Carlson R.W., Mollick J.A., et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012, 7(5):e33788.
70. Rack B., Juckstock J., Gunthner-Biller M., Andergassen U., Neugebauer J., Hepp P., Schoberth A., Mayr D., Zwingers T., Schindlbeck C., et al. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch. Gynecol. Obstet. 2012, 285(2):485-492.
71. Rack B., Schindlbeck C., Juckstock J., Andergassen U., Hepp P., Zwingers T., Friedl T.W., Lorenz R., Tesch H., Fasching P.A., et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl. Cancer Inst. 2014, 106(5).
72. Ramirez J.M., Fehm T., Orsini M., Cayrefourcq L., Maudelonde T., Pantel K., Alix-Panabieres C. Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin. Chem. 2014, 60(1):214-221.
73. Riahi R., Gogoi P., Sepehri S., Zhou Y., Handique K., Godsey J., Wang Y. A novel microchannel-based device to capture and analyze circulating tumor cells (CTCs) of breast cancer. Int. J. Oncol. 2014, 44(6):1870-1878.
74. Riethdorf S., Muller V., Zhang L., Rau T., Loibl S., Komor M., Roller M., Huober J., Fehm T., Schrader I. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 2010, 16(9):2634-2645.
75. Saucedo-Zeni N., Mewes S., Niestroj R., Gasiorowski L., Murawa D., Nowaczyk P., Tomasi T., Weber E., Dworacki G., Morgenthaler N.G. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int. J. Oncol. 2012, 41(4):1241-1250.
76. Schneck H., Blassl C., Meier-Stiegen F., Neves R.P., Janni W., Fehm T., Neubauer H. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol. Oncol. 2013, 7(5):976-986.
77. Smerage J.B., Barlow W.E., Hortobagyi G.N., Winer E.P., Leyland-Jones B., Srkalovic G., Tejwani S., Schott A.F., O'Rourke M.A., Lew D.L. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol. 2014, 32(31):3483-3489.
78. Solomayer E.F., Becker S., Pergola-Becker G., Bachmann R., Kramer B., Vogel U., Neubauer H., Wallwiener D., Huober J., Fehm T.N. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res. Treat 2006, 98(2):179-184.
79. Stott S.L., Hsu C.H., Tsukrov D.I., Yu M., Miyamoto D.T., Waltman B.A., Rothenberg S.M., Shah A.M., Smas M.E., Korir G.K. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(43):18392-18397.
80. Tewes M., Aktas B., Welt A., Mueller S., Hauch S., Kimmig R., Kasimir-Bauer S. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat. 2009, 115(3):581-590.
81. Wallwiener M., Hartkopf A.D., Baccelli I., Riethdorf S., Schott S., Pantel K., Marme F., Sohn C., Trumpp A., Rack B., et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res. Treat. 2013, 137(2):503-510.
82. Wallwiener M., Hartkopf A.D., Riethdorf S., Nees J., Sprick M.R., Schonfisch B., Taran F.A., Heil J., Sohn C., Pantel K., et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer 2015, 15:403.
83. Xenidis N., Perraki M., Apostolaki S., Agelaki S., Kalbakis K., Vardakis N., Kalykaki A., Xyrafas A., Kakolyris S., Mavroudis D., et al. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br. J. Cancer. 2013, 108(3):549-556.
84. Yu M., Bardia A., Wittner B.S., Stott S.L., Smas M.E., Ting D.T., Isakoff S.J., Ciciliano J.C., Wells M.N., Shah A.M. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339(6119):580-584.
85. Yu M., Bardia A., Aceto N., Bersani F., Madden M.W., Donaldson M.C., Desai R., Zhu H., Comaills V., Zheng Z., et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345(6193):216-220.